Phase I Study of the Hsp90 Inhibitor, PU-H71, in Patients With Refractory Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs PU H71 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- 12 Aug 2017 Status changed from recruiting to discontinued, based on the results published in the Investigational New Drugs.
- 12 Aug 2017 Results published in the Investigational New Drugs.
- 14 May 2014 Planned End Date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.